Literature DB >> 12828959

Advances in alcoholic liver disease.

Gavin Arteel1, Luis Marsano, Christian Mendez, Frederick Bentley, Craig J McClain.   

Abstract

Alcoholic liver disease (ALD) remains a major cause of morbidity and mortality worldwide. For example, the Veterans Administration Cooperative Studies reported that patients with cirrhosis and superimposed alcoholic hepatitis had a 4-year mortality of >60%. Interactions between acetaldehyde, reactive oxygen and nitrogen species, inflammatory mediators and genetic factors appear to play prominent roles in the development of ALD. The cornerstone of therapy for ALD is lifestyle modification, including drinking and smoking cessation and losing weight, if appropriate. Nutrition intervention has been shown to play a positive role on both an inpatient and outpatient basis. Corticosteroids are effective in selected patients with alcoholic hepatitis and pentoxifylline appears to be a promising anti-inflammatory therapy. Some complementary and alternative medicine agents, such as milk thistle and S-adenosylmethionine, may be effective in alcoholic cirrhosis. Treatment of the complications of ALD can improve quality of life and, in some cases, decrease short-term mortality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828959     DOI: 10.1016/s1521-6918(03)00053-2

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  41 in total

1.  Protein carbonylation in a murine model for early alcoholic liver disease.

Authors:  James J Galligan; Rebecca L Smathers; Kristofer S Fritz; L E Epperson; Lawrence E Hunter; Dennis R Petersen
Journal:  Chem Res Toxicol       Date:  2012-05-01       Impact factor: 3.739

2.  Hepatobiliary Quiz (Answers)-15 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-10-27

Review 3.  Clinical implications of oxidative stress and antioxidant therapy.

Authors:  Gerald W Dryden; Ion Deaciuc; Gavin Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2005-08

4.  Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease.

Authors:  Mirella Fraquelli; Cristina Rigamonti; Giovanni Casazza; Dario Conte; Maria Francesca Donato; Guido Ronchi; Massimo Colombo
Journal:  Gut       Date:  2007-01-25       Impact factor: 23.059

Review 5.  Reprint of: Nutrition in the Management of Cirrhosis and its Neurological Complications.

Authors:  Chantal Bémeur; Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2015-02-19

Review 6.  Nutrition in the management of cirrhosis and its neurological complications.

Authors:  Chantal Bémeur; Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2013-06-11

7.  Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats.

Authors:  Yanhao He; Qiang Liu; Yanxiang Li; Xiaofeng Yang; Weirong Wang; Tingting Li; Wei Zhang; Yuexin Cui; Chaoyun Wang; Rong Lin
Journal:  J Physiol Biochem       Date:  2015-01-28       Impact factor: 4.158

Review 8.  Role of mitochondria in alcoholic liver disease.

Authors:  Fatiha Nassir; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 9.  Integration of cellular bioenergetics with mitochondrial quality control and autophagy.

Authors:  Bradford G Hill; Gloria A Benavides; Jack R Lancaster; Scott Ballinger; Lou Dell'Italia; Zhang Jianhua; Victor M Darley-Usmar
Journal:  Biol Chem       Date:  2012-12       Impact factor: 3.915

10.  Overexpression of peroxiredoxin 6 does not prevent ethanol-mediated oxidative stress and may play a role in hepatic lipid accumulation.

Authors:  James R Roede; David J Orlicky; Aron B Fisher; Dennis R Petersen
Journal:  J Pharmacol Exp Ther       Date:  2009-04-22       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.